Metformin-induced weight loss in patients with or without type 2 diabetes/prediabetes: A retrospective cohort study. Academic Article uri icon

Overview

abstract

  • It is unknown whether weight loss outcomes differ with metformin monotherapy in patients with obesity with or without type 2 diabetes (T2DM)/prediabetes (PreDM). In this retrospective study, 6- or 12-month weight loss outcomes were compared in 222 patients with or without T2DM/preDM who completed metformin monotherapy. Average weight loss was similar between groups, euglycemic vs. T2DM/preDM (6 months: 6.5 [6.0%] vs. 6.5 [6.1%] p = 0.97; 12 months: 7.4 [6.2%] vs. 7.3 [7.7%], p = 0.92). Categorical weight losses (≥5% and ≥10% of baseline weight) were also similar. Comparable clinically significant weight loss was achieved with metformin monotherapy in patients with obesity with or without T2DM/PreDM.

publication date

  • December 30, 2020

Research

keywords

  • Diabetes Mellitus, Type 2
  • Hypoglycemic Agents
  • Metformin
  • Prediabetic State
  • Weight Loss

Identity

Scopus Document Identifier

  • 85098640399

Digital Object Identifier (DOI)

  • 10.1016/j.orcp.2020.12.005

PubMed ID

  • 33386253

Additional Document Info

volume

  • 15

issue

  • 1